Search Results - "Lebre, C."

Refine Results
  1. 1

    ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure by Rijmers, Jamie, Retmana, Irene A., Bui, Viët, Arguedas, Davinia, Lebre, Maria C., Sparidans, Rolf W., Beijnen, Jos H., Schinkel, Alfred H.

    Published in Biomedicine & pharmacotherapy (01-06-2024)
    “…Opnurasib (JDQ443) is a newly developed oral KRASG12C inhibitor, with a binding mechanism distinct from the registered KRASG12C inhibitors sotorasib and…”
    Get full text
    Journal Article
  2. 2

    Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice by Wang, Jing, Bruin, Maaike A.C., Gan, Changpei, Lebre, Maria C., Rosing, Hilde, Beijnen, Jos H., Schinkel, Alfred H.

    Published in International journal of pharmaceutics (15-05-2020)
    “…[Display omitted] Tivozanib is a potent and selective inhibitor of VEGFR1-3, recently approved by the EMA for first-line treatment of renal cell carcinoma. We…”
    Get full text
    Journal Article
  3. 3

    Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation by Herenius, Marieke M J, Oliveira, Ana S F, Wijbrandts, Carla A, Gerlag, Daniëlle M, Tak, Paul P, Lebre, Maria C

    Published in PloS one (27-02-2013)
    “…Chemerin is a specific chemoattractant for macrophages and dendritic cells (DC). In addition, it can rapidly stimulate macrophage adhesion to extracellular…”
    Get full text
    Journal Article
  4. 4

    Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c by Loos, Nancy H.C., Retmana, Irene A., Rijmers, Jamie, Wang, Yaogeng, Gan, Changpei, Lebre, Maria C., Sparidans, Rolf W., Beijnen, Jos H., Schinkel, Alfred H.

    Published in Biomedicine & pharmacotherapy (01-10-2023)
    “…Adagrasib (Krazati™) is the second FDA-approved specific KRASG12C inhibitor for non-small cell lung cancer (NSCLC) patients harboring this mutation. The impact…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Human Keratinocytes Express Functional Toll-Like Receptor 3, 4, 5, and 9 by Lebre, Maria C., van der Aar, Angelic M.G., van Baarsen, Lisa, van Capel, Toni M.M., Schuitemaker, Joost H.N., Kapsenberg, Martien L., de Jong, Esther C.

    Published in Journal of investigative dermatology (01-02-2007)
    “…Keratinocytes are continuously in contact with external stimuli and have the capacity to produce several soluble mediators. Pathogen-associated molecular…”
    Get full text
    Journal Article
  7. 7
  8. 8

    P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice by Wang, Jing, Gan, Changpei, Retmana, Irene A., Sparidans, Rolf W., Li, Wenlong, Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.

    Published in International journal of pharmaceutics (10-02-2019)
    “…[Display omitted] Quizartinib, a second-generation FLT3 inhibitor, is in clinical development for the treatment of acute myeloid leukemia. We studied its…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability by Li, Wenlong, Sparidans, Rolf W., Lebre, Maria C., Beijnen, Jos H., Schinkel, Alfred H.

    Published in Pharmaceutics (21-10-2021)
    “…Repotrectinib shows high activity against ROS1/TRK/ALK fusion-positive cancers in preclinical studies. We explored the roles of multidrug efflux transporters…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14

    Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis by Lebre, Maria C, Vergunst, Clarissa E, Choi, Ivy Y K, Aarrass, Saïda, Oliveira, Ana S F, Wyant, Tim, Horuk, Richard, Reedquist, Kris A, Tak, Paul P

    Published in PloS one (01-07-2011)
    “…The aim of this study was to provide more insight into the question as to why blockade of CCR1, CCR2, and CCR5 may have failed in clinical trials in rheumatoid…”
    Get full text
    Journal Article
  15. 15

    P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure by Wang, Jing, Susam, M. Merve, Gan, Changpei, Sparidans, Rolf W, Lebre, Maria C, Beijnen, Jos H, Schinkel, Alfred H

    Published in Pharmaceuticals (Basel, Switzerland) (01-09-2022)
    “…EAI045 is a fourth-generation allosteric tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). It targets T790M and C797S EGFR…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18
  19. 19

    Absence of Fms-like tyrosine kinase 3 ligand (Flt3L) signalling protects against collagen-induced arthritis by Ramos, M I P, Karpus, O N, Broekstra, P, Aarrass, S, Jacobsen, S E, Tak, P P, Lebre, M C

    Published in Annals of the rheumatic diseases (01-01-2015)
    “…Comprehending the mechanisms that regulate activation of autoreactive T cells and B cell antibody production is fundamental for understanding the breakdown in…”
    Get more information
    Journal Article
  20. 20

    The role of chemokines in rheumatoid arthritis and osteoarthritis by Vergunst, C. E., van de Sande, M. G. H., Lebre, M. C., Tak, P. P.

    Published in Scandinavian journal of rheumatology (01-11-2005)
    “…The directed movement of immune cells is highly dependent on the chemokine network. Chemokines are key molecules early in the embryogenesis of lymph nodes and…”
    Get full text
    Journal Article